Logo

Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

Share this
Iterum

Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

Shots:

  • The US FDA has approved Orlynvah (sulopenem etzadroxil & probenecid) to treat uUTIs in adult women, specifically addressing infections caused by E.coli, Klebsiella pneumoniae, or Proteus mirabilis, particularly when there are few or no other oral therapy available
  • Approval was based on two pivotal P-III studies (SURE 1 & REASSURE) that assessed the safety & efficacy of Orlynvah vs ciprofloxacin (SURE 1) & Augmentin (REASSURE)
  • The SURE 1 trial found that Orlynvah was superior to ciprofloxacin for fluoroquinolone-resistant infections, while REASSURE demonstrated both non-inferiority & statistical superiority to Augmentin among patients susceptible to that antibiotic. Both trials indicated well-tolerability

Ref: Iterum | Image: Iterum

Related News:- European Patent Office (EPO) Grants Approval to Biogen’s Tecfidera Patent

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions